

PharmaMar has announced the sale of Xylazel for €21.8 million

- **Xylazel is one of the leaders in the paints and varnishes market**
- **The sale has been agreed with AkzoNobel for €21.8 million**
- **This sale results in a further step towards a previously announced focus on its pharmaceutical business**

Madrid, September 20th, 2018.- PharmaMar (MSE:PHM) has announced the sale of Xylazel, consumer chemicals company belonging to the PharmaMar Group, dedicated to the production and sale of chemical products for the protection and decoration of wood and metal. In 2017 Xylazel obtained a net revenue of €20.5 million, a 6% increase on the previous year (€19.4 million), making the Company one of the market leaders in this sector, here in Spain.

The sale of Xylazel has been concluded for a cash price of €21.8 million, this being calculated on a cash-free and debt-free basis.

The buyer, AkzoNobel, has acquired 100% of the shares, which represent the whole share capital of Xylazel.

This agreement is in line with the strategy that PharmaMar initiated in 2014 with Zeltia's reverse merger, to focus on the pharmaceutical sector.

These proceeds reinforce PharmaMar's financial position.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications

of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.

About AkzoNobel

AkzoNobel has a passion for paint. We're experts in the proud craft of making paints and coatings, setting the standard in color and protection since 1792. Our world class portfolio of brands – including Dulux, International, Sikkens and Interpon – is trusted by customers around the globe. Headquartered in the Netherlands, we operate in over 80 countries and employ around 35,000 talented people who are passionate about delivering the high performance products and services our customers expect. The sale of our Specialty Chemicals business is expected to be completed by the end of 2018.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500 / +34 902 10 19 00

Email: investorrelations@pharmamar.com

Or please visit our website at www.pharmamar.com